Joydeep Goswami, Chief Strategy and Corporate Development Officer at Illumina, joined the BioLife Solutions board of directors on October 1, 2021. In his role, he is responsible for driving planning, strategic partnerships, and acquisitions.
Prior to Illumina, Mr. Goswami served as the President of Thermo Fisher Scientific’s Clinical Next-Generation Sequencing (NGS) and Oncology business unit, where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health. Goswami has held senior leadership roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at companies such as Life Technologies and Invitrogen, in addition to Thermo Fisher Scientific. He has led teams across various functions, including sales, marketing, R&D and other support functions. Mr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen. Additionally, he spent five years at McKinsey, where he specialized in strategy for pharmaceutical, medical technology and technology companies.
Mr. Goswami holds his MS, PhD in Chemical Engineering, and MBA from MIT and a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology.
What is Joydeep Goswami's net worth?
The estimated net worth of Joydeep Goswami is at least $1.10 million as of October 24th, 2025. Mr. Goswami owns 44,986 shares of BioLife Solutions stock worth more than $1,097,209 as of December 14th. This net worth approximation does not reflect any other investments that Mr. Goswami may own. Learn More about Joydeep Goswami's net worth.
How do I contact Joydeep Goswami?
Has Joydeep Goswami been buying or selling shares of BioLife Solutions?
During the last ninety days, Joydeep Goswami has sold $48,297.34 in shares of BioLife Solutions stock. Most recently, Joydeep Goswami sold 1,666 shares of the business's stock in a transaction on Friday, October 24th. The shares were sold at an average price of $28.99, for a transaction totalling $48,297.34. Following the completion of the sale, the director now directly owns 44,986 shares of the company's stock, valued at $1,304,144.14. Learn More on Joydeep Goswami's trading history.
Who are BioLife Solutions' active insiders?
BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Amy Duross (Director), Karen Foster (Insider), Joydeep Goswami (Director), Andrew Hinson (Director), Aby Mathew (VP), Geraint Phillips (SVP), Michael Rice (CEO), Garrie Richardson (CRO), Joseph Schick (Director), Marcus Schulz (CRO), Sean Werner (Chief Technology Officer), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.
Are insiders buying or selling shares of BioLife Solutions?
In the last twelve months, insiders at the medical equipment provider sold shares 87 times. They sold a total of 3,038,481 shares worth more than $76,018,405.56. The most recent insider tranaction occured on December, 4th when CFO Troy Wichterman sold 30,000 shares worth more than $771,600.00. Insiders at BioLife Solutions own 2.2% of the company.
Learn More about insider trades at BioLife Solutions. Information on this page was last updated on 12/4/2025.
